University of Strasbourg

ImmuPharma's P140 Cuts Inflammation and Fibrosis in MASH Model as Company Files International Patent for Type M Precision Medicine

- ImmuPharma published preclinical research showing its lead peptide P140 reduced both inflammation and fibrosis in mice with advanced metabolic dysfunction-associated steatohepatitis (MASH). - A dummy version of the peptide produced none of these effects, strengthening the case that the observed changes were attributable to P140 itself. - The company filed a Patent Cooperation Treaty application covering its P140 precision medicine approach, including identification and treatment of patients with the Type M immune profile. - ImmuPharma said P140 remains a core value driver and it is focused on completing a value-enhancing commercial deal in 2026.